pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk is a pharma organization headquartered in bagsværd, DK. Primary therapeutic focus areas include Diabetes, Congenital Bleeding Disorder, Acquired Bleeding Disorder, Overweight, Cardiorespiratory arrest at bir
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
turoctocog alfa pegol
Phase 3 · small molecule · Congenital Bleeding Disorder
turoctocog alfa pegol for Congenital Bleeding Disorder is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 2 ClinicalTrials.gov record(s).
Internal code NN7088-3885
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Congenital Bleeding Disorder
- Status
- completed
- Trials
- 2